hide
Free keywords:
-
Abstract:
Objective: Neurexan®, a natural pharmaceutical product sold over the counter (OTC), contains diluted plant and mineral components: passionflower, oats, coffee and zinc valerianate. Neurexan® has been investigated in patients with symptoms related to acute stress and nervousness. It was shown that stress is associated with cognitive impairments, as for example during the oddball paradigm. Previous research suggested an standard tones and two types of deviant tones (10 frequency deviant; 10 duration deviant), presented in a pseudo-randomized order.
Results: RmANOVA with within-subject factors treatment (drug/-placebo) and deviant-type (frequency/duration) showed significant treatment by deviant-type interaction (F(1, 37) = 8.828, p = 0.005, η2 = 0.193) on the latency of the mismatch negativity. The Wilcoxontest confirmed that Neurexan® significantly reduced latency of the frequency deviant (z(37) = −2.85, p = 0.004).
Conclusion: We observed a difference between the placebo and
Neurexan® for the latency of mismatch negativity to deviant tones (frequency deviant). Our findings suggest that Neurexan® induces subtle primary processing changes additionally to its postulated topdown effects. Attenuated euroendocrine stress response in healthy volunteers induced by Neurexan®. This study further explores the effects of Neurexan® on cognitive performance. Expecting that Neurexan® reduces the stress level, we hypothesized that the subjects in the placebo group would be more susceptible to distraction compared to treatment group during an oddball
paradigm coupled with an EEG measurement.
Methods: In a randomized, placebo-controlled, double-blind, twoperiod crossover trial, brain responses of 39 healthy, moderately stressed males were measured during an unattended auditory oddball paradigm via 64-channel electroencephalogram (EEG) after intake of a single dose Neurexan® or placebo. The paradigm consisted of 80 standard tones and two types of deviant tones (10 frequency deviant;
10 duration deviant), presented in a pseudo-randomized order.
Results: RmANOVA with within-subject factors treatment (drug/-placebo) and deviant-type (frequency/duration) showed significant treatment by deviant-type interaction (F(1, 37) = 8.828, p = 0.005, η2 = 0.193) on the latency of the mismatch negativity. The Wilcoxontest confirmed that Neurexan® significantly reduced latency of the frequency deviant (z(37) = −2.85, p = 0.004).
Conclusion: We observed a difference between the placebo and
Neurexan® for the latency of mismatch negativity to deviant tones (frequency deviant). Our findings suggest that Neurexan® induces subtle primary processing changes additionally to its postulated topdown effects.
